CHILDREN'S MOTRIN CHEWABLE TABLETS TABLET (CHEWABLE)

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

IBUPROFEN

Доступна с:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

код АТС:

M01AE01

ИНН (Международная Имя):

IBUPROFEN

дозировка:

50MG

Фармацевтическая форма:

TABLET (CHEWABLE)

состав:

IBUPROFEN 50MG

Администрация маршрут:

ORAL

Штук в упаковке:

24

Тип рецепта:

OTC

Терапевтические области:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0108883009; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2003-04-09

Характеристики продукта

PRODUCT
MONOGRAPH
Children’s MOTRIN
®
(Ibuprofen Oral Suspension McNeil Std., 100 mg/5
mL
)
Infants’ MOTRIN
®
(Ibuprofen Oral Suspension McNeil Std., 40
mg/mL)
Children’s/Junior Strength
MOTRIN
®
Chewable
Tablets
(Ibuprofen Tablets McNeil Std., 50 mg and 100
m
g)
Analgesic/Antipyretic
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Ontario
L3R 5L2
Submission Control #: 237473
Last Approved: February 26, 2015
Date of Revision: June 18, 2020
Children’s Motrin
®
/ Infants’ MOTRIN
®
Page 2 of 43
Table of
Contents
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS
AND
CLINICAL USE
.................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
3
WARNINGS AND PRECAUTIONS
........................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................
8
DRUG
INT
E
RACTIONS
.......................................................................................................................
10
DOSAGE AND ADM
INISTRATION
..................................................................................................
12
OVERDOSAGE
.......................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.................................................................................
14
STORAGE AND
STABILITY
...............................................................................................................
16
SPECIAL HANDLI